Is Unicycive Therapeutics Stock a Good Investment?
Unicycive Therapeutics Investment Advice | UNCY |
- Examine Unicycive Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Unicycive Therapeutics' leadership team and their track record. Good management can help Unicycive Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Unicycive Therapeutics' business and its evolving consumer preferences.
- Compare Unicycive Therapeutics' performance and market position to its competitors. Analyze how Unicycive Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Unicycive Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Unicycive Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Unicycive Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Unicycive Therapeutics is a good investment.
Sell | Buy |
Buy
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Unicycive Therapeutics Stock
Researching Unicycive Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 70.0% of the company outstanding shares are owned by institutional investors. The book value of Unicycive Therapeutics was at this time reported as 0.28. The company recorded a loss per share of 0.46. Unicycive Therapeutics had not issued any dividends in recent years.
To determine if Unicycive Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Unicycive Therapeutics' research are outlined below:
| Unicycive Therapeutics generated a negative expected return over the last 90 days | |
| Unicycive Therapeutics has high historical volatility and very poor performance | |
| Unicycive Therapeutics has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 675 K. Net Loss for the year was (30.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Unicycive Therapeutics currently holds about 10.57 M in cash with (18.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Unicycive Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 70.0% of the company outstanding shares are owned by institutional investors |
Unicycive Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Unicycive Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Unicycive Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 21st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Unicycive Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 59.16 M.Basic technical analysis of Unicycive Stock
As of the 25th of February, Unicycive Therapeutics has the Coefficient Of Variation of (2,237), risk adjusted performance of (0.02), and Variance of 26.58. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Unicycive Therapeutics, as well as the relationship between them.Unicycive Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Unicycive Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Unicycive Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Unicycive Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Unicycive Therapeutics' Outstanding Corporate Bonds
Unicycive Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Unicycive Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Unicycive bonds can be classified according to their maturity, which is the date when Unicycive Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| UniCredit 7296 percent Corp BondUS904678AQ20 | View | |
| UCGIM 2569 22 SEP 26 Corp BondUS904678AU32 | View | |
| UniCredit 5459 percent Corp BondUS904678AS85 | View | |
| UNICREDIT SPA 5861 Corp BondUS904678AF64 | View | |
| UCGIM 3127 03 JUN 32 Corp BondUS904678AY53 | View | |
| UCGIM 1982 03 JUN 27 Corp BondUS904678AW97 | View |
Understand Unicycive Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Unicycive Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.50) | |||
| Mean Deviation | 3.95 | |||
| Coefficient Of Variation | (2,237) | |||
| Standard Deviation | 5.16 | |||
| Variance | 26.58 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.24) | |||
| Total Risk Alpha | (0.28) | |||
| Treynor Ratio | (0.51) | |||
| Maximum Drawdown | 28.72 | |||
| Value At Risk | (8.06) | |||
| Potential Upside | 9.43 | |||
| Skewness | 0.7653 | |||
| Kurtosis | 1.5 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.50) | |||
| Mean Deviation | 3.95 | |||
| Coefficient Of Variation | (2,237) | |||
| Standard Deviation | 5.16 | |||
| Variance | 26.58 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.24) | |||
| Total Risk Alpha | (0.28) | |||
| Treynor Ratio | (0.51) | |||
| Maximum Drawdown | 28.72 | |||
| Value At Risk | (8.06) | |||
| Potential Upside | 9.43 | |||
| Skewness | 0.7653 | |||
| Kurtosis | 1.5 |
Consider Unicycive Therapeutics' intraday indicators
Unicycive Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Unicycive Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 43130.25 | |||
| Daily Balance Of Power | (0.75) | |||
| Rate Of Daily Change | 0.95 | |||
| Day Median Price | 0.55 | |||
| Day Typical Price | 0.55 | |||
| Price Action Indicator | (0.03) | |||
| Period Momentum Indicator | (0.03) | |||
| Relative Strength Index | 39.07 |
Unicycive Stock media impact
Far too much social signal, news, headlines, and media speculation about Unicycive Therapeutics that are available to investors today. That information is available publicly through Unicycive media outlets and privately through word of mouth or via Unicycive internal channels. However, regardless of the origin, that massive amount of Unicycive data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Unicycive Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Unicycive Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Unicycive Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Unicycive Therapeutics alpha.
Unicycive Therapeutics Corporate Management
| MPA MD | Chairman, Founder | Profile | |
| Pramod Gupta | Executive Operations | Profile | |
| John CPA | Chief Officer | Profile | |
| Douglas MBA | Executive Strategy | Profile |
Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.